Evidence map›Paper›PMID 36895129›Full record

ArticleHuman brain mapping2023

Cerebellar and subcortical atrophy contribute to psychiatric symptoms in frontotemporal dementia.

Aurélie Bussy, Jake P Levy, Tristin Best, Raihaan Patel, Lani Cupo, Tim Van Langenhove, Jørgen E Nielsen, Yolande Pijnenburg, Maria Landqvist Waldö, Anne M Remes and 34 more

Open access · goldAbstract read
In one paragraph

Article in Human brain mapping, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Neurological soft signs in neurodegenerative dementias: Results of the DemeNSS study.PCN reports : psychiatry and clinical neurosciences · 2025
    Article
  3. Article
  4. Review
  5. Observational
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

44 authors at 20 institutions in 13 countries.

Aurélie BussyComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Quebec, Canada.ORCID 0000-0001-6695-9941
Jake P LevyIntegrated Program in Neuroscience, McGill University, Montreal, Canada.
Tristin BestComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Quebec, Canada.
Raihaan PatelComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Quebec, Canada.
Lani CupoComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Quebec, Canada.
Tim Van LangenhoveDepartment of Neurology, Ghent University Hospital, Ghent, Belgium.
Jørgen E NielsenNeurogenetics Clinic & Research Lab, Danish Dementia Research Centre, Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID 0000-0003-0453-5582
Yolande PijnenburgAlzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Maria Landqvist WaldöDivision of Clinical Sciences Helsingborg, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Anne M RemesResearch Unit of Clinical Medicine, Neurology, University of Oulu, Finland.
Matthias L SchroeterClinic for Cognitive Neurology, University Clinic Leipzig, Max Planck Institute for Human Cognitive and Brain Sciences, Leipzig, Germany.
Isabel SantanaUniversity Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Florence PasquierUniversite de Lille, Lille, France.
Markus OttoDepartment of Neurology, University of Ulm, Ulm, Germany.
Adrian DanekNeurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, Germany.
Johannes LevinNeurologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, Munich, Germany.
Isabelle Le BerSorbonne Université, Paris Brain Institute-Institut du Cerveau-ICM, Inserm U1127, Paris, France.
Rik VandenbergheDepartment of Neurosciences, Laboratory for Cognitive Neurology, Leuven, Belgium.
Matthis SynofzikDepartment of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, Center for Neurodegenerative Diseases (DZNE), University of Tübingen, Tübingen, Germany.
Fermin MorenoNeuroscience Area, Biodonostia Health Research Institute, San Sebastian, Spain.
Alexandre de MendonçaFaculty of Medicine, University of Lisbon, Lisbon, Portugal.
Raquel Sanchez-ValleAlzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
Robert LaforceClinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, Quebec, Canada.
Tobias LangheinrichDivision of Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Alexander GerhardDivision of Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
Caroline GraffCenter for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Bioclinicum, Karolinska Institutet, Solna, Sweden.
Chris R ButlerNuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
Sandro SorbiDepartment of Neurofarba, University of Florence, Florence, Italy.
Lize JiskootDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Harro SeelaarDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
John C van SwietenDepartment of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
Elizabeth FingerDepartment of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.
Maria Carmela TartagliaTanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Canada.
Mario MasellisSunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
Pietro TiraboschiFondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Daniela GalimbertiDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy.
Barbara BorroniCentre for Neurodegenerative Disorders, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.ORCID 0000-0001-9340-9814
James B RoweDepartment of Clinical Neurosciences and Cambridge University Hospitals NHS Trust and Medical Research Council Cognition and Brain Sciences Unit, University of Cambridge, Cambridge, UK.
Martina BocchettaDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.ORCID 0000-0003-1814-5024
Jonathan D RohrerMunich Cluster of Systems Neurology, Munich, Germany.
Gabriel A DevenyiComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Quebec, Canada.ORCID 0000-0002-7766-1187
M Mallar ChakravartyComputational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Mental Health University Institute, Montreal, Quebec, Canada.
Simon DucharmeIntegrated Program in Neuroscience, McGill University, Montreal, Canada.
GENetic Frontotemporal dementia Initiative (GENFI)
Douglas Mental Health University Institute · CAErasmus University Rotterdam · NLHertie Institute for Clinical Brain Research · DEInserm · FRMontreal Neurological Institute and Hospital · CAAmsterdam Neuroscience · NLBiogipuzkoa Health Research Institute · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESCopenhagen University Hospital · DKDon Carlo Gnocchi Foundation · ITFondazione IRCCS Istituto Neurologico Carlo Besta · ITGhent University Hospital · BEInstitut des Sciences Cognitives Marc Jeannerod · FRKarolinska University Hospital · SELudwig-Maximilians-Universität München · DELund University · SEMRC Cognition and Brain Sciences Unit · GBMunich Cluster for Systems Neurology · DEOulu University Hospital · FISalford Royal NHS Foundation Trust · GB

Funding

Alzheimer's Society AS-JF-19a-004-517Alzheimer's Society AS-PG-16-007Department of Health BRC-1215-20014Department of Health BRC149/NS/MHMedical Research Council MR/M008525/1Medical Research Council MR/M023664/1
6 · The paper itself

Abstract

Recent studies have reported early cerebellar and subcortical impact in the disease progression of genetic frontotemporal dementia (FTD) due to microtubule-associated protein tau (MAPT), progranulin (GRN) and chromosome 9 open reading frame 72 (C9orf72). However, the cerebello-subcortical circuitry in FTD has been understudied despite its essential role in cognition and behaviors related to FTD symptomatology. The present study aims to investigate the association between cerebellar and subcortical atrophy, and neuropsychiatric symptoms across genetic mutations. Our study included 983 participants from the Genetic Frontotemporal dementia Initiative including mutation carriers and noncarrier first-degree relatives of known symptomatic carriers. Voxel-wise analysis of the thalamus, striatum, globus pallidus, amygdala, and the cerebellum was performed, and partial least squares analyses (PLS) were used to link morphometry and behavior. In presymptomatic C9orf72 expansion carriers, thalamic atrophy was found compared to noncarriers, suggesting the importance of this structure in FTD prodromes. PLS analyses demonstrated that the cerebello-subcortical circuitry is related to neuropsychiatric symptoms, with significant overlap in brain/behavior patterns, but also specificity for each genetic mutation group. The largest differences were in the cerebellar atrophy (larger extent in C9orf72 expansion group) and more prominent amygdalar volume reduction in the MAPT group. Brain scores in the C9orf72 expansion carriers and MAPT carriers demonstrated covariation patterns concordant with atrophy patterns detectable up to 20 years before expected symptom onset. Overall, these results demonstrated the important role of the subcortical structures in genetic FTD symptom expression, particularly the cerebellum in C9orf72 and the amygdala in MAPT carriers.

Indexed as

Frontotemporal DementiaAtrophyC9orf72 ProteinCerebellumHumansMagnetic Resonance ImagingC9orf72 Proteinfrontotemporal dementiageneticsmagnetic resonance imagingneuropsychiatry

Identifiers

PMID36895129
PMCPMC10089095
OpenAlexW4323811581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.